Significance of p63 amplification and overexpression in lung cancer development and prognosis.

The fight against lung cancer is greatly compromised by the lack of effective early detection strategies. Genomic abnormalities and specifically the amplification of chromosomal region 3q26-3qter in lung cancer represent a major signature of neoplastic transformation. Here, we address the significance of p53 homologue p63 mapping to 3q27 in lung tumorigenesis. We analyzed p63 gene copy number (CN) by fluorescence in situ hybridization and expression by immunohistochemistry in tissue microarrays of 217 non-small cell lung cancers (NSCLCs) and correlated them with survival. We additionally characterized our findings in a subset of 24 NSCLCs by reverse transcription-PCR and Western blotting. We analyzed p63 CN and protein expression in 41 preinvasive squamous lesions. The p63 genomic sequence was amplified in 88% of squamous carcinomas, in 42% of large cell carcinomas, and in 11% of adenocarcinomas of the lung. The predominant splice variant of p63 expressed was DeltaNp63alpha. Western analyses revealed DeltaNp63alpha expression in normal bronchus and squamous carcinomas but not in normal lung or in adenocarcinomas. Furthermore, p63genomic amplification and protein staining intensity associated with better survival. We found a significant increase in CN in preinvasive lesions graded severe dysplasia or higher. Our data demonstrate that there is early and frequent genomic amplification of p63 in the development of squamous carcinoma of the lung and that patients with NSCLC showing amplification and overexpression of p63 have prolonged survival. These observations suggest that p63 genomic amplification has an early role in lung tumorigenesis and deserves additional evaluation as a biomarker for lung cancer progression.

[1]  R. Redon,et al.  A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. , 2001, Cancer research.

[2]  N. Little,et al.  Hdmx and Mdm2 can repress transcription activation by p53 but not by p63 , 2001, Oncogene.

[3]  Ajay N. Jain,et al.  Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. , 2002, Cancer research.

[4]  B. Quade,et al.  Expression of the p53 homologue p63 in early cervical neoplasia. , 2001, Gynecologic oncology.

[5]  C. Croce,et al.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions. , 1998, Cancer research.

[6]  M. Higashiyama,et al.  Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer , 1998, Oncogene.

[7]  A. Yang,et al.  Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. , 2000, Cancer research.

[8]  S. Nomoto,et al.  ΔNp63 induces β-catenin nuclear accumulation and signaling , 2002 .

[9]  V. Rusch,et al.  p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.

[10]  F. Lanza,et al.  The abnormal p53 proteins expressed in CML cell lines are non-functional. , 1993, Leukemia.

[11]  J. Gray,et al.  Genome changes and gene expression in human solid tumors. , 2000, Carcinogenesis.

[12]  F. McKeon,et al.  Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. , 2002, Trends in molecular medicine.

[13]  K. Engeland,et al.  Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer , 2001, The Journal of pathology.

[14]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[15]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[16]  Marshall W. Anderson,et al.  Homozygous deletions of human chromosome 3p in lung tumors. , 1997, Cancer research.

[17]  P. Hall,et al.  Characterization of the expression pattern of p63α and δnp63α in benign and malignant oral epithelial lesions , 2000 .

[18]  L. Thiberville,et al.  Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. , 2001, American journal of respiratory and critical care medicine.

[19]  Xinbin Chen,et al.  p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes , 2001, Oncogene.

[20]  H. Garewal,et al.  Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling. , 1990, American journal of clinical pathology.

[21]  S. Chi,et al.  Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.

[22]  M. Dohn,et al.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. , 2001, Oncogene.

[23]  R. Odze,et al.  Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. , 2001, Human pathology.

[24]  J. Pietenpol,et al.  p53 Signaling and cell cycle checkpoints. , 2001, Chemical research in toxicology.

[25]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[26]  J. Netterville,et al.  Expression of p63 and 14-3-3σ in Normal and Hyperdifferentiated Mucosa of the Upper Aerodigestive Tract , 2002, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[27]  C. Harris,et al.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. , 1999, Cancer research.

[28]  J. Yokota,et al.  Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. , 1999, International journal of oncology.

[29]  J. Minna,et al.  Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. , 1995, JAMA.

[30]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[31]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Pietenpol,et al.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. , 2003, Molecular and cellular biology.

[33]  U. Pastorino,et al.  p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? , 2002, The Journal of pathology.

[34]  E. Schröck,et al.  Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Jen,et al.  Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma , 2000, International journal of cancer.